摘要
目的探讨18F标记的脱氧葡萄糖(18F-FDG)代谢显像在非小细胞肺癌疾病稳定期患者化疗疗效评估中的价值。方法回顾性分析28例非小细胞肺癌稳定期患者化疗前后18F-FDG代谢显像的靶/非靶摄取值变化率(ΔT/N),并随访3~12个月得到无进展生存期(PFS),分析ΔT/N与PFS之间的相关性。根据ΔT/N不同将患者分为代谢减少组、代谢无减少组,比较两组患者PFS之间差异。结果非小细胞肺癌稳定期患者化疗后ΔT/N与PFS之间呈正相关(r=0.668,P<0.01),代谢减少组PFS较代谢无明显减少组PFS显著延长[(8.0±2.5)个月比(5.3±1.2)个月,P<0.05]。结论非小细胞肺癌稳定期患者化疗后ΔT/N值的不同可预示PFS的差异。
Objective To evaluate the value of 18F-flnorodeoxyglucose （is F-FDG） metabolism imaging in evaluating the response of patients with non-small cell lung cancer （ NSCLC ） in stable disease after chemotherapy. Methods 28 patients with NSCLC in stable disease after chemotherapy admitted between September 2010 to September 2012 were retrospectively investigated. The reduction ratio of target- to-nontarget ratio （T/N） before and after chemotherapy was calculated. The patients were followed up 3 to 12 months to measure progression-free survival （PFS）. The correlation between the reduction ratio of T/N and PFS was analyzed. The patients were divided into a reduction group and a non-reduction group according to the difference of the reduction ratio of T/N and was compared the difference of the PFS. Results The reduction ratio of T/N had positive correlation with PFS （ Pearson r = 0. 668, P 〈 0. 01 ）. The PFS of the reduction group was longer than that in the non-reduction group （8. 0±2.5 mouths vs. 5.3 ± 1.2 months, P 〈 0. 05 ）. Conclusions The reduction ratio of T/N is positively correlated with PFS in NSCLC patients in stable disease after chemotherapy. It is possible to evaluate the efficacy of the treatment according to the reduction ratio of T/N.
出处
《中国呼吸与危重监护杂志》
CAS
2013年第5期461-464,共4页
Chinese Journal of Respiratory and Critical Care Medicine
关键词
非小细胞肺癌
脱氧葡萄糖
代谢显像
疾病稳定期
疗效评估
Non-small cell lung cancer
Fluorodeoxyglucose
Metabolism imaging
Stable disease
Response evaluation
